Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026. Tom Little | Reuters Novo Nordisk on Tuesday said it plans to slash the monthly list prices of its popular obesity and diabetes drugs in the U.S. by up to 50% starting in 2027, … Read more